|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 103, 33-39, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
JL Vincent, E Carlier, MR Pinsky, J Goldstein, R Naeije, P Lejeune, S Brimioulle, JL Leclerc, RJ Kahn and G Primo
The infusion of prostaglandin E1, a vasodilating substance with predominant
effects on the pulmonary vasculature, has been found effective in the
management of pulmonary hypertension associated with various diseases. The
reported experience with prostaglandin E1 after cardiac transplantation is,
however, limited. We used prostaglandin E1 in 18 patients in whom acute
right ventricular failure developed after orthotopic cardiac
transplantation. The infusion was started within 24 hours after operation
in 16 patients and was continued for up to 7 days. Maximal doses of
prostaglandin E1, administered via a central venous catheter, ranged from
30 to 120 ng/kg/min. Norepinephrine was simultaneously infused via a left
atrial catheter in 10 patients to prevent a reduction in systemic arterial
pressure. The prostaglandin E1 infusion resulted in significant reductions
in mean arterial pressure and pulmonary vascular resistance and
simultaneous increases in cardiac index and stroke index. Mean arterial
pressure was stable and left ventricular stroke work increased. The
alveolar oxygen tension/forced inspiratory oxygen index tended to decrease
during the infusion. Three patients died, two of right heart failure and
one of multiple organ failure associated with cardiac allograft rejection.
In patients in whom right ventricular failure associated with pulmonary
hypertension develops after cardiac transplantation, prostaglandin E1,
combined with norepinephrine whenever the arterial pressure declines, can
effectively reduce pulmonary artery pressures and improve global cardiac
function without compromising systemic perfusion.
ARTICLES
Prostaglandin E1 infusion for right ventricular failure after cardiac transplantation
Department of Intensive Care, Erasme University Hospital, Free University of Brussels, Belgium.
This article has been cited by other articles:
![]() |
I. M. Lang Management of acute and chronic RV dysfunction Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H61 - H67. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Stobierska-Dzierzek, H. Awad, and R. E. Michler The evolving management of acute right-sided heart failure in cardiac transplant recipients J. Am. Coll. Cardiol., October 1, 2001; 38(4): 923 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rajek, T. Pernerstorfer, J. Kastner, P. Mares, M. Grabenwoger, D. I. Sessler, G. Grubhofer, and M. Hiesmayr Inhaled Nitric Oxide Reduces Pulmonary Vascular Resistance More Than Prostaglandin E1 During Heart Transplantation Anesth. Analg., March 1, 2000; 90(3): 523 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Smith, M. P. Murphy, R. F. Appleyard, R. J. Rizzo, L. Aklog, R. G. Laurence, and L. H. Cohn Prevention of complement-induced pulmonary hypertension and improvement of right ventricular function by selective thromboxane receptor antagonism J. Thorac. Cardiovasc. Surg., March 1, 1994; 107(3): 800 - 806. [Abstract] [Full Text] |
||||
![]() |
F. Roques, S. A. M. Nashef, X. Roques, M. A. Billes, and E. Baudet Simultaneous norepinephrine-prostacyclin biatrial infusion for right ventricular failure after transplantation J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 647 - 648. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |